ClinicalTrials.gg
CompletedNCT01381913Updated Jun 27, 2011

Feasibility Trial of Neoadjuvant Chemoradiotherapy for Locally Advanced Gastric Cancer

An observational study in Gastric Cancer and Chemoradiation, sponsored by Kagawa University. Completed at 1 site in Japan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2011-06-27.

Sponsored by Kagawa University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
12
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 181 studies in Stomach Neoplasms with a site in Japan — 33 open to participants now, 55 under way, 12 of them phase 3. Stomach Neoplasms · Japan.

Enrollment
16th of 17
12 · median 369
Started
2005
with 6 others
Observational
17 of 181
3 open now
Registered
53rd of 181
by date

Among the 181 studies in Stomach Neoplasms with a site in Japan, this one is the 16th largest by enrollment of the 17 observational ones that give a count, is one of 7 that started in 2005, is one of 17 observational ones, and was the 53rd registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

33 of the 181 studies in Stomach Neoplasms with a site in Japan are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 181 studies in Stomach Neoplasms with a site in Japan, or all of them as a file.
02

Study summary

Because locally far-advanced gastric cancer combined with adjacent tissue invasion has a poor prognosis, some phase 2 and 3 clinical trials of neoadjuvant chemotherapy (NAC) are performed in Japan. However, neoadjuvant chemoradiotherapy (NACRT) achieves superior local tumor control compared with NAC. This feasibility trial explored the feasibility and safety of neoadjuvant chemoradiotherapy (NACRT) in this type of gastric cancer.

Read the detailed description

Since S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) was approved in Japan in 1999 after a large-scale clinical trial, adjuvant chemotherapy with S-1 has been the standard treatment for stage II/III gastric cancer. However, for far-advanced gastric cancer, various adjuvant chemotherapies, including S-1, have not achieved satisfactory results. Therefore, Japan Clinical Oncology Group (JCOG) is currently performing phase 2 and 3 clinical trials of neoadjuvant chemotherapy (NAC) for locally far-advanced gastric cancer. However, previous studies of NAC have reported a pathological response rate of 15-50% for the main lesion, indicating no significant effect on local tumor control.

On the other hand, other studies have reported that anticancer drugs, including S-1, have a radiosensitizing effect, and that neoadjuvant chemoradiotherapy (NACRT) achieves superior local tumor control compared with NAC. Therefore, we conducted a feasibility trial of NACRT with S-1 for locally far-advanced gastric cancer combined with adjacent tissue invasion.

03

Conditions studied

  • Gastric Cancer
  • Chemoradiation

Browse trials for

Keywords

  • Gastric cancer
  • Chemoradiotherapy
  • Adjacent tissue invasion
  • Feasibility trial
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

  • Histologically proven gastric adenocarcinoma
  • Tumor invasion of adjacent structures (T4) and/or tumors with bulky nodal metastases

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven gastric adenocarcinoma
  • Tumor invasion of adjacent structures (T4) and/or tumors with bulky nodal
  • No metastases outside of Group 2 lymph nodes
  • Neither peritoneal metastasis nor liver metastasis
  • No other distant metastasis
  • An performance status of between 0 and 2
  • No prior radiation therapy
  • Sufficient organ function

Exclusion criteria

Exclusion Criteria:

  • A synchronous or previously active
  • Insufficient oral intake
  • A history of severe allergy
  • Watery diarrhea
  • Severe co-morbidities
  • Requiring therapy for pericardial effusion or pleural effusion
  • to S-1 or radiotherapy.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
12 participants (actual)
Biospecimen retention
Samples without dna
06

Study locations

1 site
  • Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa University
    Kita, Kagawa 761-0793, Japan
07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2005, a primary completion of Dec 2008 and a completion of May 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2011
First posted
Jun 27, 2011
Start
Oct 2005
Primary completionActual
Dec 2008
CompletionActual
May 2011
Last update
Jun 27, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT01381913
Lead sponsor
Kagawa University
First posted
Jun 27, 2011
Start date
Oct 2005
Primary completion
Dec 2008
Completion
May 2011
Last update
Jun 27, 2011

Study contacts

Shinichi Yachida, M. D. Ph. D.
study director · Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa University, Kagawa, Japan
Yasuyuki Suzuki, M. D. Ph. D.
principal investigator · Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa University, Kagawa, Japan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2005. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion